Table 2.
Baseline characteristics of included in this meta-analysis.
| Study | Year | Country | Sample size | Sex (M/F) | Age | Histological type | Study design | Tumor stage | Treatment | Cutoff value | Study period | Survival endpoint | Survival analysis | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asama, H. (9) | 2018 | Japan | 72 | 40/32 | 63 (42–85) | PDAC | Retrospective | III–IV | Chemotherapy | ≥3 | 2006–2016 | OS, RFS | MVA | 8 |
| Kato, Y. (10) | 2018 | Japan | 344 | 201/137 | 64.8 | PDAC | Retrospective | I–IV | Surgery | ≥4 | 2002–2016 | OS, RFS | MVA | 9 |
| Mao, Y. S. (12) | 2020 | China | 306 | 186/120 | 62 | PDAC | Retrospective | I–III | Surgery | ≥3 | 2012–2014 | OS | UVA | 7 |
| Terasaki, F. (13) | 2021 | Japan | 307 | 182/125 | NA | PDAC | Retrospective | I–IV | Surgery+chemotherapy | ≥4 | 2007–2015 | OS, RFS | MVA | 7 |
| Wang, A. (14) | 2020 | China | 294 | 163/131 | 55.5 (29–78) | PDAC | Retrospective | I–III | Surgery | ≥3 | 2012–2019 | OS, RFS | MVA | 8 |
| Dang, C. (15) | 2021 | China | 382 | 157/161 | 57.5 (28–78) | PDAC | Prospective | I–IV | Surgery | ≥2 | 2014–2018 | OS | MVA | 9 |
| Itoh, S. (16) | 2021 | Japan | 589 | 326/263 | 71 (63–77) | PDAC | Retrospective | I–III | Surgery | ≥3 | 2004–2016 | OS, RFS | MVA | 8 |
M, male; F, female; PDAC, pancreatic ductal adenocarcinoma; OS, overall survival; RFS, recurrence-free survival; MVA, multivariate analysis; UVA, univariate analysis; NA, not available; NOS, Newcastle–Ottawa Scale.